Material Event (Form 8-K)

On March 4, 2026, Tyra Biosciences, Inc. (the "Company") agreed to issue and sell 4,000,000 shares of common stock to a large investment management firm at a purchase price of $31.50 per share. The Company expects to receive $126.0 million in gross proceeds upon settlement, before deducting fees and other expenses payable by it.

The shares of common stock are being issued as a block transaction under the Company's "at-the-market"offering program, which has been registered under the Securities Act of 1933 pursuant to a registration statement on Form S-3(File No. 333-287086)filed with the Securities and Exchange Commission on May 8, 2025. The terms of the Company's "at-the-market"offering program are described in the sales agreement prospectus, dated May 16, 2025. Copies of the registration statement, prospectus supplement and accompanying prospectus can be accessed through the Securities and Exchange Commission's website at www.sec.gov.